This trial is to find out if 90Y-DOTA-anti-CD25 basiliximab, given with fludarabine, melphalan, and total marrow and lymphoid irradiation, is an effective treatment for high-risk acute leukemia or myelodysplastic syndrome.
2 Primary · 11 Secondary · Reporting Duration: From start of therapy up to 2 years post-transplant
12 Total Participants · 1 Treatment Group
Primary Treatment: Allogeneic Hematopoietic Stem Cell Transplantation · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: